UCLA Hematology/Oncology Clinic

Los Angeles, California 90095

1 studies enrolling now · 22 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Advanced Cancer, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Bladder Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Cervical Cancer, Cervical Carcinoma, Cholangiocarcinoma

Studies at this site

• A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies — Recruiting now
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Running, not enrolling
• Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients — Stopped early
• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors — Running, not enrolling
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) — Stopped early
• Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors — Completed
• A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms — Completed
• A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia — Completed
• A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors — Completed
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 — Completed
• Tissue Procurement Substudy for Participants in Study CP-MGA271-01 — Stopped early
• Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer — Completed
• Safety Study of MGA271 in Refractory Cancer — Completed
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors — Completed
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab — Completed
• A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome — Completed
• A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer — Completed
• A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) — Completed
• A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia — Completed